AUPH News and Press, Aurinia Pharmaceuticals Inc From 05/02/22

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that it will release financial and operational results for first quarter 2022 on Tuesday, May 10, 2022, before markets open. Aurinia’s management team will host a ...

Do you like stocks with triple-digit revenue growth? Here are three companies you might want to dig into. First up is Outset Medical (NASDAQ: OM) , a healthcare company that doubled its sales last year. The next one is Aurinia Pharmaceuticals (NASDAQ: AUPH) ; analysts ar...

The shares of Canadian biotech Aurinia Pharmaceuticals (NASDAQ:AUPH) are trading lower in the morning hours Thursday after RBC Capital Markets lowered its price target, citing Omicron-driven impact for sales of the company’s lupus nephritis therapy, Lupkynis. Ahead of Aurinia’s ...

– Company seeks proposals to create and sustain community-focused programs to support underserved populations with these conditions – Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today, affirmed its commitment to individuals livi...

Presentations include new analyses of AURORA 1 and details on the ENLIGHT-LN registry Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, today an...

The shares of the commercial-stage biopharmaceutical company Aurinia Pharmaceuticals (AUPH +10.6%) have added more than a tenth on Wednesday to record the biggest intraday gain in over three months amid rising chatter on social media. Currently, about 3.8 million Aurinia (NASDAQ:AUPH) shares ...

Aurinia Pharmaceuticals (NASDAQ:AUPH) rose 2.8% on a report that a European-based investor group is campaigning for the biotech to begin a strategic review. Aurinia holders, led by Switzerland-based MKT Tactical Fund, has written to the AUPH chairman, asking that the board to hire a bank...

Aurinia Pharmaceuticals, along with biotechs in general, has been beaten down recently. I explore the reasons specific to Aurinia and then compare recent results to my valuation model. My model turns out to be very conservative and it still arrives at a target price of $75 for AUP...

The commercial-stage biotech, Aurinia Pharmaceuticals (AUPH -4.7%), is trading lower for the third straight session on Wednesday to reach a seven-month low after several Wall Street analysts trimmed their price targets on the stock citing the company’s lackluster Q4 2021 results. ...

Gainers: Mullen Automotive (NASDAQ:MULN) +126%. Renewable Energy Group (NASDAQ:REGI) +40%. IntriCon (NASDAQ:IIN) +37%. First Horizon (NYSE:FHN) +29%. Nordic American Tankers (NYSE:NAT) +27%. NeuroSense (NASDAQ:NRSN) +26%. CorMedix (NASDAQ:CRMD) +24%. Reata Pharmaceuticals (NASDAQ:RETA) +22%. ...